Developer docs
API playgroundTry for free, no card

Search company profiles

Celldex Therapeutics

Full company profile

uuid0002ozs

Namestring
Celldex Therapeutics
Legal namestring
Celldex Therapeutics, Inc.
Websiteurl
celldex.com
Company typeenum
Public
Founded yearint
1980
Descriptiontext

Celldex Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal and bispecific antibody therapeutics for mast cell-mediated allergic, inflammatory, and autoimmune diseases. The company's lead program, barzolvolimab (CDX-0159), is a humanized monoclonal antibody that potently inhibits KIT, a receptor tyrosine kinase required for mast cell function and survival, and is advancing through the largest Phase 3 program in antihistamine-refractory chronic spontaneous urticaria (CSU) — the EMBARQ-CSU1 and EMBARQ-CSU2 trials enrolled 1,939 patients across 43 countries and over 500 sites, with topline data expected Q4 2026 and a planned BLA submission in 2027. The second core program, CDX-622, is a novel bispecific antibody that simultaneously neutralizes thymic stromal lymphopoietin (TSLP) and depletes mast cells via stem cell factor (SCF) starvation, currently in Phase 1b for asthma. Celldex's pipeline also targets cold urticaria, symptomatic dermographism, prurigo nodularis, and atopic dermatitis, leveraging a proprietary antibody platform with in-house discovery, clinical development, and GMP manufacturing capabilities across four US locations.

Celldex has no marketed products and currently generates no material product revenue. Its business model is a pre-commercial biopharma model funded by periodic public equity raises — most recently a $345 million offering in April 2026 — with future revenue intended to come from US pharmaceutical product sales following regulatory approval of barzolvolimab. The planned go-to-market is enterprise field sales targeting allergists, dermatologists, and immunology specialists, supported by a newly hired Chief Commercial Officer with prior blockbuster immunology launch experience. Celldex is publicly traded on NASDAQ under ticker CLDX, was incorporated in Delaware, and is headquartered in Hampton, New Jersey, with approximately 101–250 employees distributed across clinical, research, manufacturing, and operations sites in New Jersey, Connecticut, and Massachusetts.

Short descriptiontext

Celldex Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal and bispecific antibody therapeutics for mast cell-mediated allergic, inflammatory, and autoimmune diseases, with lead Phase 3 program barzolvolimab in chronic spontaneous urticaria and planned BLA submission in 2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersHampton, United States
HQ citystring
Hampton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
monoclonal antibody therapeutics, bispecific antibody platform, inflammatory disease treatments, mast cell therapies, immunology drug development
Industry1 code
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Product Revenue (Future)
TypeOne Time License
Description

Celldex is a clinical-stage biotechnology company with no current marketed products or revenue. The company is preparing for commercialization of barzolvolimab with Phase 3 data expected Q4 2026 and planned BLA submission in 2027. Revenue will come from pharmaceutical product sales upon regulatory approval.

biospace.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Celldex Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based immunotherapies for allergic, inflammatory, and autoimmune diseases. Its core programs are barzolvolimab (CDX-0159), a monoclonal antibody inhibitor of KIT that depletes mast cells for chronic spontaneous urticaria and other mast cell-mediated indications, and CDX-622, a bispecific antibody neutralizing TSLP and stem cell factor for asthma and Type 2 inflammatory diseases. Neither product is yet approved or commercialized; barzolvolimab is in Phase 3 with planned BLA submission in 2027.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 64% of CSU patients with angioedema at baseline remained angioedema-free at Week 76 (7 months after completing treatment)
+4 more records
Product overview1 text field

Celldex Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based immunotherapies for allergic, inflammatory, and autoimmune disorders. The company operates two core therapeutic programs: barzolvolimab (CDX-0159), a KIT antagonist monoclonal antibody targeting mast cell-mediated diseases including chronic spontaneous urticaria (CSU), cold urticaria, symptomatic dermographism, prurigo nodularis, and atopic dermatitis; and CDX-622, a bispecific antibody targeting TSLP and mast cell depletion for asthma and allergic inflammatory conditions. Barzolvolimab is advancing through Phase 3 trials for CSU with topline data expected Q4 2026 and a planned BLA submission in 2027, while CDX-622 is in Phase 1 development.

Product and service1 record
1Barzolvolimab (CDX-0159)
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Allakos
TypeDirect peer
Description

Clinical-stage biotech developing antibody therapeutics (lirentelimab) targeting mast cells and eosinophils for inflammatory diseases including chronic urticaria. Directly comparable in mechanism (mast cell modulation) and indication overlap with Celldex.

TypeEmerging player
Description

Commercial-stage biotech developing FcRn antagonist efgartigimod (Vyvgart) with expanding indications into chronic inflammatory diseases including chronic urticaria. Comparable as a high-growth antibody company targeting immunological diseases with limited treatment options.

TypeBroad incumbent
Description

Mid-cap biopharma with commercial immunology products (Opzelura cream) and pipeline assets in CSU and other inflammatory diseases. Comparable as a competing antibody developer in mast cell and Type 2 inflammation indications.

TypeBroad incumbent
Description

Large biopharma with multiple commercial immunology assets (e.g., Tezspire for severe asthma via TSLP pathway, Otezla) that compete or overlap with Celldex's pipeline. Comparable as a major antibody developer in mast cell-mediated and Type 2 inflammatory diseases.

TypeBroad incumbent
Description

Large biopharma with Dupixent (dupilumab), which is in late-stage development for chronic spontaneous urticaria - the same indication as Celldex's lead barzolvolimab. Comparable as a developer of antibody-based immunology therapeutics competing in the same end markets.

TypeBroad incumbent
Description

Markets Xolair (omalizumab), the current standard of care for antihistamine-refractory CSU. Directly comparable as a competitor in the lead indication Celldex is targeting with barzolvolimab.

TypeDirect peer
Description

Clinical-stage biotech developing mast cell-targeted therapies (e.g., briquilimab, an anti-c-Kit antibody) for chronic urticaria and other mast cell-driven diseases. Highly comparable as a direct competitor to barzolvolimab in the mast cell depletion mechanism space.

TypeBroad incumbent
Description

Global biopharma co-developing Dupixent with Regeneron, with active CSU program (lirentelimab in-licensed from Allakos for CSU). Comparable as a commercial-stage immunology competitor directly pursuing the barzolvolimab lead indication.

TypeEmerging player
Description

Late-stage dermatology-focused biotech with commercial immunology products (Zoryve). Comparable as a US-focused specialty immunology/dermatology company targeting indications like atopic dermatitis and prurigo nodularis that overlap with Celldex's pipeline expansion plans.

TypeEmerging player
Description

Clinical-stage immunology biotech developing sonelokimab, a tri-specific Nanobody targeting IL-17A/F and serum albumin, in hidradenitis suppurativa and other inflammatory skin diseases. Comparable as a clinical-stage immunology company pursuing novel antibody mechanisms.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Celldex Therapeutics

Biopharmaceuticalscelldex.com

Celldex Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal and bispecific antibody therapeutics for mast cell-mediated allergic, inflammatory, and autoimmune diseases, with lead Phase 3 program barzolvolimab in chronic spontaneous urticaria and planned BLA submission in 2027.

What Celldex Therapeutics does

Celldex Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal and bispecific antibody therapeutics for mast cell-mediated allergic, inflammatory, and autoimmune diseases. The company's lead program, barzolvolimab (CDX-0159), is a humanized monoclonal antibody that potently inhibits KIT, a receptor tyrosine kinase required for mast cell function and survival, and is advancing through the largest Phase 3 program in antihistamine-refractory chronic spontaneous urticaria (CSU) — the EMBARQ-CSU1 and EMBARQ-CSU2 trials enrolled 1,939 patients across 43 countries and over 500 sites, with topline data expected Q4 2026 and a planned BLA submission in 2027. The second core program, CDX-622, is a novel bispecific antibody that simultaneously neutralizes thymic stromal lymphopoietin (TSLP) and depletes mast cells via stem cell factor (SCF) starvation, currently in Phase 1b for asthma. Celldex's pipeline also targets cold urticaria, symptomatic dermographism, prurigo nodularis, and atopic dermatitis, leveraging a proprietary antibody platform with in-house discovery, clinical development, and GMP manufacturing capabilities across four US locations.

Celldex has no marketed products and currently generates no material product revenue. Its business model is a pre-commercial biopharma model funded by periodic public equity raises — most recently a $345 million offering in April 2026 — with future revenue intended to come from US pharmaceutical product sales following regulatory approval of barzolvolimab. The planned go-to-market is enterprise field sales targeting allergists, dermatologists, and immunology specialists, supported by a newly hired Chief Commercial Officer with prior blockbuster immunology launch experience. Celldex is publicly traded on NASDAQ under ticker CLDX, was incorporated in Delaware, and is headquartered in Hampton, New Jersey, with approximately 101–250 employees distributed across clinical, research, manufacturing, and operations sites in New Jersey, Connecticut, and Massachusetts.

Celldex Therapeutics firmographics

Firmographics
Name
Celldex Therapeutics
Legal name
Celldex Therapeutics, Inc.
Website
https://celldex.com
Company type
Public
Founded year
1980
Operating status
Operating
Headcount range
251–500 employees
Short description
Celldex Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal and bispecific antibody therapeutics for mast cell-mediated allergic, inflammatory, and autoimmune diseases, with lead Phase 3 program barzolvolimab in chronic spontaneous urticaria and planned BLA submission in 2027.
Ownership category
akta.pro rank

Celldex Therapeutics industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Monoclonal antibody therapeutics
  • Bispecific antibody platform
  • Inflammatory disease treatments
  • Mast cell therapies
  • Immunology drug development

Where Celldex Therapeutics is headquartered

Location

Headquarters

HQ city
Hampton
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Celldex Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Product Revenue (Future): Celldex is a clinical-stage biotechnology company with no current marketed products or revenue. The company is preparing for commercialization of barzolvolimab with Phase 3 data expected Q4 2026 and planned BLA submission in 2027. Revenue will come from pharmaceutical product sales upon regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Celldex Therapeutics product offering

Product offering

Core offering

Celldex Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based immunotherapies for allergic, inflammatory, and autoimmune diseases. Its core programs are barzolvolimab (CDX-0159), a monoclonal antibody inhibitor of KIT that depletes mast cells for chronic spontaneous urticaria and other mast cell-mediated indications, and CDX-622, a bispecific antibody neutralizing TSLP and stem cell factor for asthma and Type 2 inflammatory diseases. Neither product is yet approved or commercialized; barzolvolimab is in Phase 3 with planned BLA submission in 2027.

Product overview

Celldex Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based immunotherapies for allergic, inflammatory, and autoimmune disorders. The company operates two core therapeutic programs: barzolvolimab (CDX-0159), a KIT antagonist monoclonal antibody targeting mast cell-mediated diseases including chronic spontaneous urticaria (CSU), cold urticaria, symptomatic dermographism, prurigo nodularis, and atopic dermatitis; and CDX-622, a bispecific antibody targeting TSLP and mast cell depletion for asthma and allergic inflammatory conditions. Barzolvolimab is advancing through Phase 3 trials for CSU with topline data expected Q4 2026 and a planned BLA submission in 2027, while CDX-622 is in Phase 1 development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Barzolvolimab (CDX-0159)

Quantifiable outcome

  • 64% of CSU patients with angioedema at baseline remained angioedema-free at Week 76 (7 months after completing treatment)
  • +4 more outcomes

Companies that use Celldex Therapeutics

Customer profile

Segments5 records

Ideal customer profiles3 records

Celldex Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Celldex Therapeutics partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Celldex Therapeutics competitors and assessment

Company assessment

Direct peers

  • Allakos: Clinical-stage biotech developing antibody therapeutics (lirentelimab) targeting mast cells and eosinophils for inflammatory diseases including chronic urticaria. Directly comparable in mechanism (mast cell modulation) and indication overlap with Celldex.
  • Jasper Therapeutics: Clinical-stage biotech developing mast cell-targeted therapies (e.g., briquilimab, an anti-c-Kit antibody) for chronic urticaria and other mast cell-driven diseases. Highly comparable as a direct competitor to barzolvolimab in the mast cell depletion mechanism space.

Emerging players

  • argenx: Commercial-stage biotech developing FcRn antagonist efgartigimod (Vyvgart) with expanding indications into chronic inflammatory diseases including chronic urticaria. Comparable as a high-growth antibody company targeting immunological diseases with limited treatment options.
  • Arcutis Biotherapeutics: Late-stage dermatology-focused biotech with commercial immunology products (Zoryve). Comparable as a US-focused specialty immunology/dermatology company targeting indications like atopic dermatitis and prurigo nodularis that overlap with Celldex's pipeline expansion plans.
  • MoonLake Immunotherapeutics: Clinical-stage immunology biotech developing sonelokimab, a tri-specific Nanobody targeting IL-17A/F and serum albumin, in hidradenitis suppurativa and other inflammatory skin diseases. Comparable as a clinical-stage immunology company pursuing novel antibody mechanisms.

Broad incumbents

  • Incyte: Mid-cap biopharma with commercial immunology products (Opzelura cream) and pipeline assets in CSU and other inflammatory diseases. Comparable as a competing antibody developer in mast cell and Type 2 inflammation indications.
  • Amgen: Large biopharma with multiple commercial immunology assets (e.g., Tezspire for severe asthma via TSLP pathway, Otezla) that compete or overlap with Celldex's pipeline. Comparable as a major antibody developer in mast cell-mediated and Type 2 inflammatory diseases.
  • Regeneron Pharmaceuticals: Large biopharma with Dupixent (dupilumab), which is in late-stage development for chronic spontaneous urticaria - the same indication as Celldex's lead barzolvolimab. Comparable as a developer of antibody-based immunology therapeutics competing in the same end markets.
  • Novartis: Markets Xolair (omalizumab), the current standard of care for antihistamine-refractory CSU. Directly comparable as a competitor in the lead indication Celldex is targeting with barzolvolimab.
  • Sanofi: Global biopharma co-developing Dupixent with Regeneron, with active CSU program (lirentelimab in-licensed from Allakos for CSU). Comparable as a commercial-stage immunology competitor directly pursuing the barzolvolimab lead indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Celldex Therapeutics social profiles

Digital presence

Celldex Therapeutics compliance and trust

Trust signal

Compliance1 record

Celldex Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Celldex Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Celldex Therapeutics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Celldex Therapeutics M&A and investment

M&A and investment

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celldex Therapeutics

What does Celldex Therapeutics do?

Celldex Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based immunotherapies for allergic, inflammatory, and autoimmune diseases. Its core programs are barzolvolimab (CDX-0159), a monoclonal antibody inhibitor of KIT that depletes mast cells for chronic spontaneous urticaria and other mast cell-mediated indications, and CDX-622, a bispecific antibody neutralizing TSLP and stem cell factor for asthma and Type 2 inflammatory diseases. Neither product is yet approved or commercialized; barzolvolimab is in Phase 3 with planned BLA submission in 2027.

Is Celldex Therapeutics a public or private company?

Celldex Therapeutics is a public company. It is classified as public and is currently operating.

When was Celldex Therapeutics founded?

Celldex Therapeutics was founded in 1980. It employs 251 to 500 people.

Where is Celldex Therapeutics based?

Celldex Therapeutics is headquartered in Hampton, United States, in the North America region.

How does Celldex Therapeutics make money?

One revenue line is on record: product Revenue (Future).

Who are Celldex Therapeutics's main competitors?

Direct peers on record are Allakos and Jasper Therapeutics. Emerging players are argenx, Arcutis Biotherapeutics and MoonLake Immunotherapeutics. Broad incumbents are Incyte, Amgen, Regeneron Pharmaceuticals, Novartis and Sanofi.

Does Celldex Therapeutics have an API?

No public API is recorded for Celldex Therapeutics.

What industry is Celldex Therapeutics in?

Celldex Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StFollowing Earnings And Shelf Filing Is Celldex Therapeutics (CLDX) Undervalued?Celldex Therapeutics reported Q3 earnings and filed a universal shelf registration, with shares down 31.28% over 90 days. Analysts give a $29.51 fair value, but a DCF model values the stock at $5.24, leaving the valuation split between pipeline optimism and cash-flow concerns.Defense WorldCelldex Therapeutics (NASDAQ:CLDX) Given New $68.00 Price Target at Canaccord Genuity GroupCanaccord Genuity raised its price target on Celldex Therapeutics to $68 from $60, keeping a buy rating. Other analysts also adjusted targets, with an average rating of Moderate Buy and average target of $64.08. The stock opened at $31.24, and the company reported a loss of $0.96 per share for the quarter.American Banking and Market NewsCelldex Therapeutics Targets 2027 Filing for Barzolvolimab After Phase 3 ResultsCelldex Therapeutics plans to submit a biologics license application for barzolvolimab in 2027, using full 52-week Phase 3 data. The company expects to present 24-week efficacy data in February 2027 and has $650 million in cash. It also plans to pursue a premium, value-based price and expand teams ahead of potential commercialization.American Banking and Market NewsHead to Head Survey: Oncobiologics (NASDAQ:OTLK) and Celldex Therapeutics (NASDAQ:CLDX)Oncobiologics and Celldex Therapeutics are compared on valuation, risk, earnings, and analyst ratings. Oncobiologics has higher revenue and earnings, but Celldex trades at a lower price-to-earnings ratio. Analysts favor Oncobiologics with a higher consensus price target and upside.American Banking and Market NewsCelldex Therapeutics, Inc. $CLDX Stock Purchased by Candriam S.C.A.Candriam S.C.A. raised its Celldex Therapeutics stake by 7.8% in Q3, buying 37,351 shares to hold 518,476 shares (0.66% of the company). Other funds also adjusted positions, and analysts rate the stock a Moderate Buy with a consensus price target of $63.08.YahooCelldex Reports Third Quarter Financial Results and Provides Corporate UpdateCelldex reported Q3 2026 results, including a $75.6 million net loss and $650.3 million in cash. The company cited best-in-disease Phase 3 results for barzolvolimab in chronic urticaria, with a BLA submission anticipated in 2027.YahooCelldex to Present at Upcoming Investor ConferencesCelldex management will participate in fireside chats at the Guggenheim Healthcare Innovation Conference on November 9 and the Evercore Healthcare Conference on December 1, 2026. Webcasts will be available on the company's investor page for 90 days after each event.FinancialContent Business PageCelldex to Present at Upcoming Investor ConferencesCelldex management will participate in fireside chats at the Guggenheim Healthcare Innovation Conference on November 9 and the Evercore Healthcare Conference on December 1, 2026. Webcasts will be available on the company's investor website for 90 days.American Banking and Market NewsCelldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Has Consensus Target Price of $63.08Analysts rate Celldex Therapeutics a Moderate Buy with a consensus 12-month price target of $63.08. The company reported Q2 EPS of -$0.94, beating the -$1.06 consensus, but revenue of $0.02 million missed the $0.73 million estimate. Analysts expect a fiscal-year EPS of -$4.17.MarketBeatCelldex Therapeutics, Inc. $CLDX Shares Sold by Assenagon Asset Management S.A.Assenagon Asset Management reduced its Celldex stake by 43.6% in Q3, selling 343,774 shares and holding 444,922 shares worth $14.42 million. Analysts rate the stock a Moderate Buy with an average target of $61.92, while Celldex reported a loss of $0.94 per share for the quarter.